Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
A new study presented at the IASLC 2026 World Conference on Lung Cancer showed that adding the drug zipalertinib to standard platinum-pemetrexed chemotherapy significantly improves progression-free survival in patients with advanced non-small cell lung cancer (NSCLC) who have specific EGFR gene mutations. The phase 3 REZILIENT 3 trial, which randomly assigned 279 patients to receive either the combination or chemotherapy alone, found a 50% reduction in the risk of disease progression or death with the combination treatment.
The improvement was consistent across subgroups, including patients with brain metastases. The addition of zipalertinib also led to a higher response rate to treatment and longer median duration of response compared to chemotherapy alone. While the combination was generally well-tolerated, it was associated with a higher frequency of adverse events, primarily manageable hematologic events and EGFR-related toxicities.
Further follow-up of the REZILIENT 3 trial is ongoing to assess overall survival and other outcomes.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
